1
|
Huelsboemer L, Boroumand S, Boroumand T, Vafa AZ, Parikh N, Chiarella LS, Knoedler L, Stögner VA, Hung P, Sadigh S, Haykal S, Pomahac B, Kauke-Navarro M. Long-term posttransplant-related bone volumetric changes in eight face transplant recipients - A single-center retrospective case series. J Plast Reconstr Aesthet Surg 2025; 101:220-230. [PMID: 39848075 DOI: 10.1016/j.bjps.2024.11.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2024] [Revised: 10/25/2024] [Accepted: 11/21/2024] [Indexed: 01/25/2025]
Abstract
BACKGROUND The long-term stability of allograft or native bone in facial vascularized composite allograft (fVCA) recipients is unclear. This study quantified long-term bone volume changes in facial transplants. METHODS Computed tomography scans of eight fVCA recipients (2011-2023) were analyzed with Materialise Mimics. Native bone (soft tissue-only VCAs, n=4) and allotransplanted bone (n=4) were compared. Median bone volumes were assessed for significance using the WilcoxonRanked-Sum Test. RESULTS Mean follow-up was 10 years (range 5-13). A significant median decrease in both mandibular (-6520 mm3; p=0.0078) and maxillary (-3548 mm3; p=0.0078) bone volumes was seen in all patients, irrespective of bone origin. Median bone volume loss was -9.92% in the bony allograft cohort and -22.60% in the soft tissue-only cohort, respectively. The histopathological analysis of the limited samples (n=2) showed physiological bone even after ten years. CONCLUSION Patients with allotransplanted bone showed less pronounced volume loss compared to those with native bone receiving soft tissue-only allografts. This finding suggests that allotransplanted vascularized bone in fVCAs may not be a primary target of chronic rejection processes that compromise bone volume stability and functionality. Bone volume changes are likely influenced by multiple factors, such as tooth loss, nutrition, chronic immunosuppression (e.g., steroids), mechanical stress/load, varying bone remodeling rates, and other medical comorbidities. Further research is needed to clarify the factors affecting bone volume and remodeling after fVCA.
Collapse
Affiliation(s)
- Lioba Huelsboemer
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA
| | - Sam Boroumand
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA
| | - Tara Boroumand
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA; University of California, San Francisco School of Dentistry, San Francisco, CA, USA
| | - Aliyar Zahedi Vafa
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA
| | - Neil Parikh
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA
| | - Laetitia S Chiarella
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA; Department of Plastic and Reconstructive Surgery, Institute for Musculoskeletal Medicine, Muenster University, Germany; Department of Plastic, Reconstructive and Aesthetic Surgery, Hand Surgery, Fachklinik Hornheide, Muenster, Germany
| | - Leonard Knoedler
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA; University of Regensburg, School of Medicine, Regensburg, Germany
| | - Viola A Stögner
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA
| | - Peter Hung
- Yale School of Medicine, Department of Radiology and Biomedical Imaging, New Haven, CT, USA
| | - Sam Sadigh
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Siba Haykal
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA
| | - Bohdan Pomahac
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA
| | - Martin Kauke-Navarro
- Yale School of Medicine, Division of Reconstructive and Plastic Surgery, New Haven, CT, USA.
| |
Collapse
|
2
|
Stogov MV, Dyuryagina OV, Silant'eva TA, Shipitsyna IV, Kireeva EA, Stepanov MA. Evaluation of Biocompatibility of New Osteoplastic Xenomaterials Containing Zoledronic Acid and Strontium Ranelate. TRAUMATOLOGY AND ORTHOPEDICS OF RUSSIA 2023; 29:57-73. [DOI: 10.17816/2311-2905-2035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/03/2023]
Abstract
Background. The problem of improving the functional characteristics of implanted devices and materials used in traumatology and orthopedics is a topical issue.
Aim of the study to study biocompatibility of bovine bone matrix xenomaterials modified by zoledronic acid and strontium ranelate when implanted into the bone defect cavity.
Methods. The study was performed on 24 male rabbits of the Soviet Chinchilla breed. Test blocks of bone matrix were implanted into the cavity of bone defects of the femur. Group 1 animals (n = 8, control group) were implanted with bone xenogenic material (Bio-Ost osteoplastic matrix). Group 2 animals (n = 8) were implanted with bone xenogenic material impregnated with zoledronic acid. Group 3 animals (n = 8) were implanted with bone xenogeneic material impregnated with strontium ranelate. Supercritical fluid extraction technology was used to purify the material and impregnate it with zoledronic acid and strontium ranelate. Radiological, pathomorphological, histological and laboratory (hematology and blood biochemistry) diagnostic methods were used to assess biocompatibility. Follow-up period was 182 days after implantation.
Results. It was found out that on the 182nd day after implantation the median area of the newly-formed bone tissue in the defect modeling area in Group 1 was 79%, in Group 2 0%, in Group 3 67%. In Group 2 the maximum area by this period was filled with connective tissue 77%. Median relative area of implanted material fragments in Group 1 was 4%, in Group 2 23%, in Group 3 15%. No infection or material rejection was observed in animals of all groups. There were no signs of intoxication or prolonged systemic inflammatory reaction. Laboratory parameters did not change significantly over time. One animal in each group experienced one-time increase in C-reactive protein level against the background of leukocytosis. Two animals in Group 1 had a slight migration of implanted material under the skin, one animal developed arthritis of the knee joint.
Conclusion. Osteoplastic materials based on bovine bone xenomatrix and filled with zoledronic acid and strontium ranelate have acceptable values of biocompatibility including their safety profile.
Collapse
|
3
|
Zhao Y, Cooper DKC, Wang H, Chen P, He C, Cai Z, Mou L, Luan S, Gao H. Potential pathological role of pro-inflammatory cytokines (IL-6, TNF-α, and IL-17) in xenotransplantation. Xenotransplantation 2019; 26:e12502. [PMID: 30770591 DOI: 10.1111/xen.12502] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 12/04/2018] [Accepted: 01/18/2019] [Indexed: 12/15/2022]
Abstract
The major limitation of organ transplantation is the shortage of available organs from deceased human donors which leads to the deaths of thousands of patients each year. Xenotransplantation is considered to be an effective way to resolve the problem. Immune rejection and coagulation dysfunction are two major hurdles for the successful survival of pig xenografts in primate recipients. Pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-17, play important roles in many diseases and in allotransplantation. However, the pathological roles of these pro-inflammatory cytokines in xenotransplantation remain unclear. Here, we briefly review the signaling transduction and expression regulation of IL-6, TNF-α, and IL-17 and evaluate their potential pathological roles in in vitro and in vivo models of xenotransplantation. We found that IL-6, TNF-α, and IL-17 were induced in most in vitro or in vivo xenotransplantation model. Blockade of these cytokines using gene modification, antibody, or inhibitor had different effects in xenotransplantation. Inhibition of IL-6 signaling with tocilizumab decreased CRP but did not increase xenograft survival. The one possible reason is that tocilizumab can not suppress IL-6 signaling in porcine cells or organs. Other drugs which inhibit IL-6 signaling need to be investigated in xenotransplantation model. Inhibition of TNF-α was beneficial for the survival of xenografts in pig-to-mouse, rat, or NHP models. Blockade of IL-17 using a neutralizing antibody also increased xenograft survival in several animal models. However, the role of IL-17 in the pig-to-NHP xenotransplantation model remains unclear and needs to be further investigated. Moreover, blockade of TNF-α and IL-6 together has got a better effect in pig-to-baboon kidney xenotransplantation. Blockade two or even more cytokines together might get better effect in suppressing xenograft rejection. Better understanding the role of these cytokines in xenotransplantation will be beneficial for choosing better immunosuppressive strategy or producing genetic modification pig.
Collapse
Affiliation(s)
- Yanli Zhao
- Department of Nephrology, Shenzhen Longhua District Central Hospital, Guangdong Medical University Affiliated Longhua District Central Hospital, Shenzhen, China.,Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen, China.,Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University Affiliated Longhua District Central Hospital, Shenzhen, China
| | - David K C Cooper
- Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama
| | - Huiyun Wang
- Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University Affiliated Longhua District Central Hospital, Shenzhen, China
| | - Pengfei Chen
- Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University Affiliated Longhua District Central Hospital, Shenzhen, China
| | - Chen He
- Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen, China
| | - Zhiming Cai
- Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen, China
| | - Lisha Mou
- Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen, China
| | - Shaodong Luan
- Department of Nephrology, Shenzhen Longhua District Central Hospital, Guangdong Medical University Affiliated Longhua District Central Hospital, Shenzhen, China
| | - Hanchao Gao
- Department of Nephrology, Shenzhen Longhua District Central Hospital, Guangdong Medical University Affiliated Longhua District Central Hospital, Shenzhen, China.,Shenzhen Xenotransplantation Medical Engineering Research and Development Center, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen, China.,Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University Affiliated Longhua District Central Hospital, Shenzhen, China
| |
Collapse
|